Longeveron, Inc. (LGVN)
1.71
-0.07
(-3.93%)
USD |
NASDAQ |
Nov 05, 16:00
Longeveron Enterprise Value : -4.072M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -4.072M |
| November 04, 2026 | -3.85M |
| November 03, 2026 | -3.85M |
| November 02, 2026 | -4.072M |
| October 30, 2026 | -4.199M |
| October 29, 2026 | -3.945M |
| October 28, 2026 | -3.85M |
| October 27, 2026 | -4.009M |
| October 26, 2026 | -4.405M |
| October 23, 2026 | -4.421M |
| October 22, 2026 | -4.453M |
| October 21, 2026 | -4.960M |
| October 20, 2026 | -4.738M |
| October 19, 2026 | -5.087M |
| October 16, 2026 | -5.087M |
| October 15, 2026 | -4.738M |
| October 14, 2026 | -4.009M |
| October 13, 2026 | -2.676M |
| October 12, 2026 | -1.725M |
| October 09, 2026 | -1.630M |
| October 08, 2026 | -1.979M |
| October 07, 2026 | -1.757M |
| October 06, 2026 | -2.042M |
| October 05, 2026 | -1.534M |
| October 02, 2026 | -1.312M |
| Date | Value |
|---|---|
| October 01, 2026 | -1.281M |
| September 30, 2026 | -0.9636M |
| September 29, 2026 | -0.8684M |
| September 28, 2026 | -1.154M |
| September 25, 2026 | -0.583M |
| September 24, 2026 | -0.2658M |
| September 23, 2026 | -1.249M |
| September 22, 2026 | -0.8684M |
| September 21, 2026 | -1.725M |
| September 18, 2026 | -1.598M |
| September 17, 2026 | -0.9002M |
| September 16, 2026 | 11.69M |
| September 15, 2026 | 12.26M |
| September 14, 2026 | 12.45M |
| September 11, 2026 | 13.75M |
| September 10, 2026 | 11.57M |
| September 09, 2026 | 11.38M |
| September 08, 2026 | 11.60M |
| September 04, 2026 | 12.10M |
| September 03, 2026 | 11.38M |
| September 02, 2026 | 12.01M |
| September 01, 2026 | 11.91M |
| August 31, 2026 | 12.39M |
| August 28, 2026 | 11.82M |
| August 27, 2026 | 12.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.073M |
| Revenue (Quarterly) | 0.287M |
| Total Expenses (Quarterly) | 6.36M |
| EPS Diluted (Quarterly) | -1.936 |
| Gross Profit Margin (Quarterly) | -13.59% |
| Profit Margin (Quarterly) | -2.12K% |
| Earnings Yield | -593.6% |
| Normalized Earnings Yield | -593.60 |